Cencora

(New York Stock Exchange)
Back to all articles
Bullish +72

Cencora stock sets specialty-led path for fiscal 2027

Acquisition Company update Dividend AI-generated analysis

πŸ“ˆ Cencora reported fiscal fourth-quarter revenue of $88.4 billion, a 5.5% increase from the prior-year quarter.

πŸ’° Adjusted diluted earnings per share surged 21.4% year-over-year to $4.66, driven by higher gross profit and the OneOncology acquisition.

πŸ”„ The company reorganized its fiscal 2027 structure to center on specialty services, which are expected to grow revenue at 9% to 14%.

πŸ’΅ Cencora raised its quarterly dividend by 10% to $0.66 per share, payable on November 30.

πŸš€ Management forecasts fiscal 2027 adjusted diluted EPS between $19.40 and $19.75, implying 8% to 10% growth.

🀝 The company plans to acquire American Oncology Network and sell its stake in Profarma to optimize the portfolio.

Bullish Signals
  • Cencora reported a significant 21.4% year-over-year increase in adjusted diluted earnings per share to $4.66, driven by higher gross profit and the OneOncology acquisition.
  • The company raised its quarterly dividend by 10% to $0.66 per share, signaling confidence in cash flow generation and shareholder returns.
  • Management expects the specialty division to be the primary growth engine for fiscal 2027, with revenue projected to grow between 9% and 14%.
  • Cencora reaffirmed its long-term target of 10% to 14% adjusted diluted EPS growth, maintaining a strong trajectory for shareholder value.
  • The acquisition of OneOncology contributed directly to improved operating performance and supported the transition toward higher-margin specialty services.
Full Analysis
Cencora Inc. reported strong fiscal fourth-quarter results on November 4, 2026, with revenue rising 5.5% to $88.4 billion and adjusted diluted earnings per share increasing 21.4% year-over-year to $4.66. The company also posted GAAP EPS of $2.71, a significant turnaround from a loss in the prior period, driven by higher gross profit and the acquisition of OneOncology. Management has reorganized its reporting structure for fiscal 2027 to prioritize specialty services, which are projected to outpace traditional distribution growth. The specialty division is expected to grow revenue between 9% and 14%, compared to 4% to 6% for the pharmaceutical distribution segment, reflecting a strategic shift toward higher-growth areas. For fiscal 2027, Cencora forecasts adjusted diluted earnings per share between $19.40 and $19.75, representing 8% to 10% growth from the prior year. The company also raised its quarterly dividend by 10% to $0.66 per share and plans further portfolio moves, including the acquisition of American Oncology Network and the sale of its stake in Profarma.